These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML). Stubbs MC; Krivtsov AV Curr Protoc Pharmacol; 2017 Sep; 78():14.42.1-14.42.19. PubMed ID: 28892146 [TBL] [Abstract][Full Text] [Related]
26. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia. Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225 [TBL] [Abstract][Full Text] [Related]
27. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Itskovich SS; Gurunathan A; Clark J; Burwinkel M; Wunderlich M; Berger MR; Kulkarni A; Chetal K; Venkatasubramanian M; Salomonis N; Kumar AR; Lee LH Nat Commun; 2020 May; 11(1):2369. PubMed ID: 32398749 [TBL] [Abstract][Full Text] [Related]
28. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Li BE; Ernst P Exp Hematol; 2014 Dec; 42(12):995-1012. PubMed ID: 25264566 [TBL] [Abstract][Full Text] [Related]
29. Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia. Chu Y; Chen Y; Li M; Shi D; Wang B; Lian Y; Cheng X; Wang X; Xu M; Cheng T; Shi J; Yuan W Cancer Sci; 2019 Jul; 110(7):2200-2210. PubMed ID: 31050834 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of histone demethylase JMJD1C attenuates cardiac hypertrophy and fibrosis induced by angiotensin II. Zhang S; Lu Y; Jiang C J Recept Signal Transduct Res; 2020 Aug; 40(4):339-347. PubMed ID: 32122211 [TBL] [Abstract][Full Text] [Related]
31. The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Li H; Mar BG; Zhang H; Puram RV; Vazquez F; Weir BA; Hahn WC; Ebert B; Pellman D Blood; 2017 Jan; 129(4):497-508. PubMed ID: 27756750 [TBL] [Abstract][Full Text] [Related]
33. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation. Chen Y; Ernst P Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857 [TBL] [Abstract][Full Text] [Related]
34. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424 [TBL] [Abstract][Full Text] [Related]
35. AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase. Yoshihama Y; LaBella KA; Kim E; Bertolet L; Colic M; Li J; Shang X; Wu CJ; Spring DJ; Wang YA; Hart T; DePinho RA Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34475205 [TBL] [Abstract][Full Text] [Related]